Trejo-Nava CA

Idioma: Español
Referencias bibliográficas: 71
Paginas: 86-108
Archivo PDF: 330.51 Kb.

RESUMEN

La pirámide poblacional muestra un desplazamiento hacia los grupos de edad cada vez más avanzada y, considerando que la enfermedad arterial coronaria continúa ocupando uno de los primeros lugares como causa de muerte en todo el mundo, es de esperarse un número cada vez mayor de pacientes seniles afectos de cardiopatía isquémica en nuestra práctica diaria. El paciente senil es comúnmente excluido de las investigaciones clínicas, por lo que las evidencias para su manejo son escasas o supuestas de los resultados obtenidos de la población general. Los adultos mayores tienen características fisiológicas y fisiopatologías específicas; son casos «complejos» para su abordaje diagnóstico y terapéutico, pero además tiene un estado comórbido, lo que realza el reto que como médicos tenemos, ya que debemos no sólo enfocarnos en la cardiopatía, sino en las funciones hepática, renal, neurológica, entre otras sin perder de vista la calidad de vida, las interacciones farmacológicas y el estado emocional del paciente anciano. Por ello, resulta de gran interés conocer y difundir los aspectos específicos (basados en la evidencia actual) del paciente adulto mayor con enfermedad arterial coronaria que permitan mejorar su atención y tal vez estimular el desarrollo de nuevas investigaciones.

REFERENCIAS (EN ESTE ARTÍCULO)

1. Farhan Majeed, Mark D. Kelemen. Acute coronary syndromes in the elderly. Clin Geriatr Med. 2007; 23: 425-440.

2. David B Loran, Joseph B Zwischenberger. Thoracic Surgery in the Elderly. J Am Coll Surg. 2004; 199 (4): 773-784.

3. http://cvdinfobase.ca/Scripts/gcvdmap.dll?name=GCVI&cmd

4. =START

5. Alexander K, Newby L, Cannon C. Acute coronary care in the elderly, part I: Non-ST segment elevation acute coronary syndromes: A scientific statement for healthcare professionals from the American Heart Association Council on Clinical Cardiology: In collaboration with the Society of Geriatric Cardiology. Circulation. 2007; 115: 2549.

6. Alexander K, Newby L, Armstrong P. Acute coronary care in the elderly, part II: ST-segment-elevation myocardial infarction: A scientific statement for healthcare professionals from the American Heart Association Council on Clinical Cardiology: In collaboration with the Society of Geriatric Cardiology. Circulation. 2007; 115: 2570-2577.

7. Schwartz JB, Zipes DP. Cardiovascular disease in the elderly. En: Bonow RO, Mann DL, Zipes DP, Libby P. Tratado de medicina cardiovascular. 9a edición. Editorial Elsevier; 2012: 1727-1756.

8. Wenger NK. Cardiovascular disease in the elderly. Curr Probl Cardiol. 1992; 17: 609-690.

9. Forman D, Wenger NK. What do the recent American Heart Association/American College of Cardiology Foundation Clinical Practice Guidelines tell us about the evolving management of coronary heart disease in older adults? Journal of Geriatric Cardiology. 2013; 10: 123-128.

10. Roger VL, Go AS, Lloyd-Jones DM et al. Heart Disease and Stroke Statistics--2011 Update: A Report From the American Heart Association. Circulation. 2011; 123: e18-e209.

11. Roger VL, Go AS, Lloyd-Jones DM et al. Heart Disease and Stroke Statistics--2012 Update: A Report From the American Heart Association. Circulation. 2011; 125: e2-e220.

12. Galasso G, Piscione F, Furbatto F, Leosco D, Pierri A, De Rosa R, Cirillo P et al. Abciximab in elderly with Acute Coronary Syndrome invasively treated: Effect on outcome Original Research Article. International Journal of Cardiology. 2008; 130 (3): 380-385.

13. Savonitto S, Cavallini C, Petronio AS, Murena E, Antonicelli R, Sacco A, Steffenino G, Bonechi F et al. Italian Elderly ACS trial investigators early aggressive versus initially conservative treatment in elderly patients with non-st-segment elevation acute coronary syndrome: A randomized controlled trial original research article JACC: Cardiovascular Interventions. 2012; 5 (9): 906-916.

14. Libby P. Mechanisms of acute coronary syndromes and their implications for therapy. N Engl J Med. 2013; 368: 2004-2013.

15. Kovacic JC, Moreno P, Nabel EG, Hachinski V, Fuster V. Cellular senescence, vascular disease, and aging part 2 of a 2 part review: Clinical vascular disease in the elderly. Circulation. 2011; 123: 1900-1910.

16. Kovacic JC, Moreno P, Nabel EG, Hachinski V, Fuster V.. Cellular senescence, vascular disease, and aging part 1 of a 2 part review: clinical vascular disease in the elderly. Circulation. 2011; 122: 987-970.

17. Kitzman DW, Daniel KR. Diastolic heart failure in the elderly. Clin Geriatr Med. 2007; 23: 83-106.

18. Aurigemma GP, Gaasch WH, McLaughlin M et al. Reduced left ventricular systolic pump performance and depressed myocardial contractile function in patients 65 years of age with normal ejection fraction and a high relative wall thickness. Am J Cardiol. 1995; 76 (10): 702-705.

19. Mendes LA, Davidoff R, Cupples LA et al. Congestive heart failure in patients with coronary artery disease: the gender paradox. Am Heart J. 1997; 134: 207-12.

20. Rich MW, Kitzman DW. Heart failure in octogenarians: a fundamentally different disease. Am J Geriatr Cardiol. 2000; 9 (Suppl 5): 97-104.

21. Ogawa T, Spina RJ, Martin WH et al. Effect of aging, sex, and physical training on cardiovascular responses to exercise. Circulation. 1992; 86: 494-503.

22. Spina RJ, Ogawa T, Miller TR et al. Effect of exercise training on left ventricular performance in older women free of cardiopulmonary disease. Am J Cardiol. 1993; 71: 99-194.

23. Quinn GR, Fang MC. Atrial fibrillation stroke prevention in older adults. Clin Geriatr Med. 2012; 28: 617-634.

24. Servansky JE, Haponik EF. Respiratory failure in elderly patients. Clin Geriatr Med. 2003; 19: 205-224.

25. Torres M, Moayedi S. Evaluation of the acutely dyspneic elderly patient. Clin Geriatr Med. 2007; 23: 307-325.

26. Shiber JR, Santana J. Dyspnea. Med Clin North Am. 2006; 90: 453-479.

27. Morgan WC, Hodge HL. Diagnostic evaluation of dyspnea. Am Fam Physician. 1998; 57 (4): 711-716.

28. Imperato J, Sanchez LD. Pulmonary emergencies in the elderly. Emerg Med Clin North Am. 2006; 24: 317-338.

29. Podrazik PM, Schwartz JB. Cardiovascular pharmacology of the elderly. Cardiol Clin. 1999; 17: 17-34.

30. Yuen GJ. Altered pharmacokinetics in the elderly. Clin Geriatr Med. 1990; 6: 257-267.

31. Ali Raza J, Movahed A. Use of cardiovascular medications in the elderly. International Journal of Cardiology. 2002; 85: 203-215.

32. Roger VL, Go AS, Lloyd-Jones DM et al. Heart disease and stroke statistics 2011 Update: A report from the American Heart Association. Circulation. 2011; 123: e18-e209.

33. Roger VL, Go AS, Lloyd-Jones DM et al. Heart disease and stroke statistics 2012 update: A report from the American Heart Association. Circulation. 2012; 125: e2-e220.

34. Fleg JL, Schulman S, O’Connor F, Becker LC, Gerstenblith G,Clulow JF et al. Effects of acute beta-adrenergic receptor blockade on age-associated changes in cardiovascular performance during dynamic exercise. Circulation. 1994; 90: 2333-2341.

35. Jneid H, Anderson JF, Wright RS, Adams CD, Bridges CR, Casey DE et al. 2012 ACCF/AHA Focused Update Incorporated Into the ACCF/AHA 2007 Guidelines for the management of patients with unstable angina/Non-ST-elevation myocardial infarction. J Am Coll Cardiol. 2013; 61 (23): e179-e347.

36. Fihn SD, Gardin JM, Abrams J, Berra K, Blankenship JC, Dallas PA, Douglas PS et al. 2012 ACCF/AHA/ACP/AATS/PCNA/SCAI/STS Guideline for the diagnosis and management of patients with stable ischemic heart disease: executive summary. Circulation. 2012; 126: 3097-3137.

37. Steg G, James SK, Atar D, Badano LP, Blömstrom-Lundqvist C, Borger MA, Di Mario C et al. ESC Guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation. European Heart Journal. 2012; 33: 2569-2619.

38. Ridker PM, Buring JE, Rifai N, Cook NR. Development and validation of improved algorithms for the assessment of global cardiovascular risk in women. The Reynolds Risk Score. JAMA. 2007; 297 (6): 611-61.

39. Yusuf S, Zhao F, Mehta SR, Chrolavicius S, Tognoni G, Fox KK. Clopidogrel in unstable angina to prevent recurrent events trial investigators. Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation. N Engl J Med. 2001; 345: 494-502.

40. Wiviott SD, Braunwald E, McCabe CH et al. TRITON-TIMI 38 Investigators. Prasugrel versus clopidogrel in patients with acute coronary syndromes. N Engl J Med. 2007; 357: 2001-2015.

41. Capodanno DE, Angiolillo DJ. Antithrombotic therapy in the elderly. J Am Coll Cardiol. 2010; 56: 1683-1692.

42. Villanueva-Benito I, Solla-Ruíz I, Paredes-Galán E, Díaz Castro O, Calvo-Iglesias FE, Baz-Alonso JA, Iñiguez-Romo A. Impacto pronóstico del abordaje intervencionista en el paciente muy anciano con síndrome coronario agudo sin elevación del segmento ST. Rev Esp Cardiol. 2011; 64 (10): 853-861.

43. Guagliumi G, Stone GW, Cox DA et al. Outcome in elderly patients undergoing primary coronary intervention for acute myocardial infarction: results from the Controlled Abciximab and Device Investigation to Lower Late Angioplasty Complications (CADILLAC) trial. Circulation. 2004; 110: 1598-604.

44. The ESPRIT Investigators. Novel dosing regimen of eptifibatide in planned coronary stent implantation (ESPRIT): a randomised, placebo controlled trial. Lancet. 2000; 356: 2037-2044.

45. Lopes RD, Alexander KP, Marcucci G et al. Outcomes in elderly patients with acute coronary syndromes randomized to enoxaparin vs. unfractionated heparin: results from the SYNERGY trial. Eur Heart J. 2008; 29: 1827-1833.

46. Lopes RD, Alexander KP, Manoukian SV et al. Advanced age, antithrombotic strategy, and bleeding in non-ST-segment elevation acute coronary syndromes: results from the ACUITY (Acute Catheterization and Urgent Intervention Triage Strategy) trial. J Am Coll Cardiol. 2009; 53: 1021-1030.

47. Fox KA, Bassand JP, Mehta SR et al. OASIS 5 Investigators. Influence of renal function on the efficacy and safety of fondaparinux relative to enoxaparin in non ST-segment elevation acute coronary syndromes. Ann Intern Med. 2007; 147: 304-310.

48. Deedwania PC. New oral anticoagulants in elderly patients with atrial fibrillation. The American Journal of Medicine. 2013; 126: 289-296.

49. Lip GYH, Nieuwlaat R, Pisters R et al. Refining clinical risk stratification for predicting stroke and thromboembolism in atrial fibrillation using a novel risk factor based approach: the Euro Heart survey on atrial fibrillation. Chest. 2010; 137: 263-272.

50. Pisters R, Lane DA, Nieuwlaat R, de Vos CB, Crijns HJGM, Lip GYH. A Novel User-Friendly Score (HAS-BLED) To assess 1-year risk of major bleeding in patients with atrial fibrillation. CHEST. 2010; 138 (5): 1093-1100.

51. Skolnick AH, Alexander KP, Chen AY et al. Characteristics, management, and outcomes of 5,557 patients age or 90 years with acute coronary syndromes: results from the CRUSADE Initiative .J Am Coll Cardiol. 2007; 49: 1790-1797.

52. Connolly SJ, Ezekowitz MD, Yusuf S et al. The RE-LY Steering Committee and investigators. Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med. 2009; 361: 1139 -1151.

53. Krumholz HM. Cardiopatía isquémica en el anciano. Rev Esp Cardiol. 2001; 54: 819 826.

54. Biondi Zoccai G, Abbate A, D’Ascenzo F, Presutti D, Peruzzi M, Cavarretta, Marullo AGM et al. Percutaneous coronary intervention in nonagenarians: pros and cons. Journal of Geriatric Cardiology. 2013; 10: 82-90.

55. Wiviott SD, Cannon CP, Morrow DA et al. Differential expression of cardiac biomarkers by gender in patients with unstable angina/non-ST elevation myocardial infarction: a TACTICS-TIMI 18 (treat angina with aggrastat and determine cost of therapy with an invasive or conservative strategy-thrombolysis in myocardial infarction 18) substudy. Circulation. 2004; 109: 580-586.

56. Nasser TK, Fry ET, Annan K et al. Comparison of six-month outcome of coronary artery stenting in patients 65, 65-75, and 75 years of age. Am J Cardiol. 1997; 80: 998-1001.

57. Lee BJ, Herbison P, Wong CK. Is the advantage of coronary bypass graft surgery over percutaneous coronary intervention in diabetic patients with severe multivessel disease influenced by the status of insulin requirement? Journal of Geriatric Cardiology. 2014; 11: 83-89.

58. Roques F, Nashef SA, Michel P, Gauducheau E, de Vincentiis C, Baudet E, Cortina J et al. Risk factors and outcome in European cardiac surgery: analysis of the EuroSCORE multinational database of 19030 patients. Eur J Cardiothorac Surg. 1999; 15 (6): 816-22.

59. Hoffman SN, TenBrook JA, Wolf MP et al. A meta-analysis of randomized controlled trials comparing coronary artery bypass graft with percutaneous transluminal coronary angioplasty: oneto eight-year outcomes. J Am Coll Cardiol. 2003; 41: 1293-1304.

60. Daemen J, Boersma E, Flather M et al. Long-term safety and efficacy of percutaneous coronary intervention with stenting and coronary artery bypass surgery for multivessel coronary artery disease: a meta-analysis with 5-year patient-level data from the ARTS, ERACI-II, MASS-II, and SoS trials. Circulation. 2008; 118: 1146-1154.

61. Ji-Hong WANG, Wei LIU, Xin DU, Chang-Sheng MA, Xue-Si WU. Long term outcomes of saphaneous vein graft intervention in elderly patients with prior coronary artery bypass graft. Journal of Geriatric Cardiology. 2014; 11: 26-31.

62. Menezes AR, Lavie CJ, Milani RV, Arena RA, Church TS. Cardiac rehabilitation and exercise therapy in the elderly: Should we invest in the aged? Journal of Geriatric Cardiology. 2012; 9: 68-75.

63. Dzavik V, Ghali WA, Norris C, Mitchell LB, Koshal A, Saunders LD,Galbraith PD, Hui W, Faris P, Knudtson ML. Long-term survival in 11,661 patients with multivessel coronary artery disease in the era of stenting: a report from the Alberta Provincial Project for Outcome Assessment in Coronary Heart Disease (APPROACH) Investigators. Am Heart J. 2001; 142: 119-126.

64. Simoons ML, Windecker S. Chronic stable coronary artery disease: drugs vs. revascularization. European Heart Journal. 2010; 31: 530-541.

65. Fox KM. Efficacy of perindopril in reduction of cardiovascular events among patients with stable coronary artery disease: randomised, double-blind, placebo controlled, multicentre trial (the EUROPA study). Lancet. 2003; 362: 782-788.

66. Pfisterer M. Long-term outcome in elderly patients with chronic angina managed invasively versus by optimized medical therapy: four-year follow-up of the randomized Trial of Invasive versus Medical therapy in Elderly patients (TIME). Circulation. 2004; 110: 1213-1218.

67. Shaw LJ, Berman DS, Maron DJ, Mancini GB, Hayes SW, Hartigan PM, Weintraub WS, O’Rourke RA et al. Optimal medical therapy with or without percutaneous coronary intervention to reduce ischemic burden: results from the Clinical Outcomes Utilizing Revascularization and Aggressive Drug Evaluation (COURAGE) trial nuclear substudy. Circulation. 2008; 117: 1283-1291.

68. Mehran R, Aymong ED, Nikolsky E, Lazic Z, Iakovou I, Fahy M et al. A simple risk score for prediction of contrast-induced nephropathy after percutaneous coronary intervention: development and initial validation. J Am Coll Cardiol. 2004; 44: 1393-1399.

69. Charlson ME, Pompei P, Ales KL, MacKenzie CR. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis. 1987; 40 (5): 373-338.

70. Singh M, Lennon RJ, Holmes DR Jr, Bell MR, Rihal CS. Correlates of procedural complications an simple integer risk score for percutaneous coronary intervention. J Am Coll Cardiol. 2002 (40): 387-393.

71. Reed MC, Moscucci M, Smith DE, Share D, LaLonde T, Mahmood SA, D’Haem C, McNamara R, Greenbaum A, Gurm HS. The relative renal safety of iodixanol and low-osmolar contrast media in patients undergoing percutaneous coronary intervention: Insights from blue cross blue shield of Michigan Cardiovascular Consortium (BMC2). Journal of Invasive Cardiology. 2010; 22: 467-472.